Search

Management of the neck in patients treated with primary chemoradiation for cancer of the laryngopharynx with a clinically positive neck remains an area of controversy. The neck may be managed in 1 of 3 ways: by observation, by planned neck dissection, or by salvage neck dissection. Observation of the neck can be done in patients who have a complete or near-complete response to treatment and have a negative positron emission tomography (PET) scan result. Evidence for this approach comes from recent studies that have reported low regional recurrence rates.1–6 Planned neck dissection was carried out in the past in patients with N2 and N3 neck disease irrespective of the response to chemoradiation. The neck dissection was carried out 6 weeks after completion of chemoradiation; this approach had the advantage of carrying out the neck dissection before the onset of fibrosis, thereby making the neck dissection technically similar in complexity to a nonchemoradiation neck dissection. Evidence for a policy of planned neck dissection comes from studies that have shown the presence of tumor in neck dissection specimens in patients who have complete or near-complete radiologic and clinical response in the neck.4,7–10 Before the introduction of fluorodeoxyglucose–positron emission tomography (FDG-PET) scanning, planned neck dissection was a common method for managing the neck after chemoradiation. Some groups still practice this policy because of limitations or unavailability of PET. However, in general, most centers now reserve neck dissection for salvage for residual or recurrent neck disease. Salvage neck dissection is normally carried out if there is clinical or radiologic evidence of neck disease after completion of chemoradiation. Before 2005, our policy was to assess response by clinical examination and CT imaging at 6 to 12 weeks after completion of chemoradiation. However, since 2005, we have been using 18FDG-PET for the assessment of tumor response. The 18FDG-PET is usually carried out at 12 weeks after completion of chemoradiation to minimize any false-positive results from residual inflammation from chemoradiation. Salvage neck dissection in patients who have neck disease as detected by PET is therefore carried out 12 weeks after chemoradiation. This has the disadvantage of making the operation technically more difficult because of the onset of fibrosis. As a consequence, some have advocated the use of selective and superselective salvage neck dissections in these patients.11–14 Clearly there is evidence in the literature to support the practice of planned, as well as salvage neck dissection. However, there is little in the literature that describes what the impact of viable tumor in such neck dissection specimen has on prognosis. In this study, we have examined our own experience of patients undergoing comprehensive neck dissection either as a planned procedure or salvage procedure in the time period before our routine use of PET. The objective was to determine whether viable tumor had a negative impact on prognosis, even after removal of residual tumor by neck dissection.

This was a two-year project that had two major components: 1) the demonstration of a PV-electrolysis system that has separate PV system and electrolysis unit and the hydrogen generated is to be used to power a fuel cell based vehicle; 2) the development of technologies for generation of hydrogen through photoelectrochemical process and bio-mass derived resources. Development under this project could lead to the achievement of DOE technical target related to PEC hydrogen production at low cost. The PEC part of the project is focused on the development of photoelectrochemical hydrogen generation devices and systems using thin-film silicon based solar cells. Two approaches are taken for the development of efficient and durable photoelectrochemical cells; 1) An immersion-type photoelectrochemical cells (Task 3) where the photoelectrode is immersed in electrolyte, and 2) A substrate-type photoelectrochemical cell (Task 2) where the photoelectrode is not in direct contact with electrolyte. Four tasks are being carried out: Task 1: Design and analysis of DC voltage regulation system for direct PV-to-electrolyzer power feed Task 2: Development of advanced materials for substrate-type PEC cells Task 3: Development of advanced materials for immersion-type PEC cells Task 4: Hydrogen production through conversion of biomass-derived wastes

Objective To describe the clinicopathologic and radiologic features of solitary fibrous tumors of the head and neck. Design Retrospective analysis. Setting Tertiary referral center that performs head and neck surgical oncology. Patients Twelve patients with solitary fibrous tumors of the head and neck identified from the pathology and soft tissue tumor databases at Memorial Sloan-Kettering Cancer Center, New York, NY, from 1990 to 2004. All cases were reviewed by 3 experienced pathologists, 1 of whom is an experienced soft tissue tumor pathologist. The diagnosis was confirmed by microscopic features on hematoxylin-eosin staining and by positive staining for CD34 and Bcl2 on immunohistochemical analysis. Tumors were scored for mitotic activity, cellularity, nuclear pleomorphism, necrosis, and the presence of a malignant component. Details on patient characteristics, tumor characteristics, previous treatment and surgery, adjuvant treatment, and outcome were recorded from clinical records. Results Solitary fibrous tumors occurred in patients over a wide age range (27-78 years; median age, 52 years). Seven patients (58%) were women, and 5 (42%) were men. Most tumors presented as a slow-growing painless mass with a duration ranging from 2 months to 5 years. The tumors ranged from 1 × 1 cm to 6 × 5 cm. Patients presented with a subcutaneous mass of the scalp or face in 4 cases, intraoral mass in 4, sinonasal mass in 3, and paraspinal mass in 1. Computed tomographic and/or magnetic resonance imaging scans of 7 of the 12 patients showed well-circumscribed tumors that enhanced strongly with contrast. Treatment for all of the patients was surgical resection. Pathologic findings showed that 9 tumors were benign and 3 were malignant. Three patients had a positive surgical resection margin. All patients were alive at a median follow-up of 8 months (range, 1-76 months). Local recurrence occurred in 1 patient who had positive surgical margins 3 years after the initial surgery. Conclusions Solitary fibrous tumors of the head and neck region are rare and most commonly benign. The diagnosis depends on microscopic and immunohistochemical features, although imaging may help. Patients with these tumors can be safely treated with local excision, but tumors with positive margins require close follow-up over several years owing to the potential for late local recurrence.

Objective To report our experience in treating patients with malignant minor salivary gland tumors of the larynx. Design Thirty-three-year retrospective study. Setting Tertiary referral center specializing in head and neck surgery. Patients Twelve patients with malignant minor salivary gland tumors of the larynx were identified from a search of the institutional databases and pathology records at Memorial Sloan-Kettering Cancer Center, New York, NY, between the years 1970 and 2003. All slides were independently reviewed by 2 pathologists (R.G. and D.C.). Details on patient and tumor characteristics, as well as treatment and surgical outcome, were recorded. Results Ten patients (83%) had adenoid cystic carcinoma and 2 (17%) had myoepithelial carcinoma. Five (42%) were located in the supraglottis and 7 (58%) in the subglottis. Ten (83%) had surgery (6 with adjuvant radiotherapy) and 2 (17%) were treated with radiotherapy alone. Of the 10 patients who had surgery, total laryngectomy was required in 6 (60%), supraglottic horizontal laryngectomy in 2 (20%), and cricotracheal resection in 2 (20%). With a median follow-up of 55 months (range, 1-194 months), 10 patients are alive, 6 of whom have no evidence of disease. Seven patients (58%) developed recurrent disease, 2 of whom had local recurrence alone, 1 had regional recurrence alone, 3 had distant recurrence alone, and 1 had local and distant recurrence. Conclusions Up to 60% of patients with malignant minor salivary gland tumors of the larynx will develop recurrent disease locally, regionally, or at distant sites. In adenoid cystic carcinoma, regional recurrence is rare, but distant recurrence is common and may occur up to 10 years after the index therapy. For both adenoid cystic and myoepithelial carcinoma, partial surgery is possible in selected cases, but because of the high propensity for submucosal spread and perineural and lymphovascular invasion, total laryngectomy is usually recommended.